Industry observers see red flags in how House Democrats have structured the language related to comparative effectiveness in the economic stimulus bill, with questions on how the money will be spent as well as its potential to leave the door open for cost-effectiveness comparisons of medical products
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.
The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.
Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.
